Scholars Central

Conference abstractPublished 3 Aug 2015

Brazilian pharmaceutical regulation on productive partnerships for development of priority drugs

Authors: Elizabeth Alves Fernandes

Tauil & Chequer Advogados Associado a Mayer Brown LLP, Brazil

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Productive Partnerships for Development (âÂ?Â?PDPsâÂ?) of priority drugs are in the center of the discussions about the supply of drugs for the Brazilian public market. Under PDPs, public laboratories receive technology for priority drugs which have been developed by private pharmaceutical companies. The public laboratory then on sells the drugs to the Brazilian government. The purpose is that the public laboratories are able to supply the public sector in the long term and the PDP ultimately equips it with the technology (including the access to cell banks) and skills to do so. However, until the technology transfer has occurred âÂ?Â? which demands a certain maturity - the public laboratory buys the product manufactured by the private company.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Elizabeth Alves Fernandes”